New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2013
11:52 EDTHNZ, EXAS, SPPI, ZIOP, WHXOptions with increasing implied volatility: ZIOP EXAS WHX SPPI HNZ
News For ZIOP;EXAS;WHX;SPPI;HNZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
12:33 EDTZIOPStocks with call strike movement; ZIOP AVP
Ziopharm (ZIOP) October 14 call option implied volatility increased 8% to 97, Avon Products (AVP) July 11 call option implied volatility decreased 2% to 57 according to IVolatility.
05:51 EDTZIOPStocks with implied volatility movement; ZIOP MNKD
Subscribe for More Information
April 14, 2015
11:36 EDTZIOPZiopharm cancels out of two meetings, Bloomberg reports
Subscribe for More Information
April 13, 2015
08:01 EDTEXASExact Sciences says Cologuard receives coverage by several health plans in Q1
Since the start of 2015, several insurers began covering Cologuard as a noninvasive colon cancer screening test. In addition to several smaller regional providers, insurance plans covering the test now include: Anthem Blue Cross and Blue Shield, a leading national health plan with more than 37 million members across 14 states, Tufts Health Plan, with more than 1 million members across Massachusetts and Rhode Island and ranked the number one health plan for quality in the country for its Commercial plans and its Medicaid plans, CareFirst BlueCross BlueShield PPO, with 2.3 million eligible members across Maryland, District of Columbia and Northern Virginia, Excellus BCBS WNY, with more than 1.4 million members across Western New York and Dean Health Plan, insuring more than 272,037 members across Central Wisconsin.
April 9, 2015
09:17 EDTSPPICourt lifts injunction on sales of generic copy of Spectrum's Fusilev
The U.S. Court of Appeals for the Federal Circuit yesterday issued an order that lifted a temporary injunction put in place March 6 that had blocked Novartis' (NVS) Sandoz unit from selling a generic version of Spectrum Pharmaceuticals' (SPPI) colorectal cancer treatment Fusilev. The appeals court ruled that Spectrum failed to meet the requirements for an injunction pending appeal.
09:00 EDTSPPISpectrum revenue under 'major threat' after ruling, says Roth Capital
Roth Capital says an appeals court ruling yesterday denying Spectrum's injunction motion aimed to block Sandoz's generic Fusilev launch represents a "major threat" to Spectrum's revenue stream. Roth expects erosion of the company's Fusilev sales once the generic is launched and maintained a Neutral rating on the stock.
April 8, 2015
07:53 EDTEXASExact Sciences survey results positive, says JMP Securities
After surveying 102 high-FIT/FOBT prescribing primary care and ob/gyn physicians who have been prescribing ColoGuard for at least four months, JMP Securities says that utilization of Exact Sciences' ColoGuard is increasing at a rapid pace. The firm adds that doctors are becoming more optimistic regarding the potential long-term penetration of ColoGuard into the market. The firm reiterates a $27 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use